Latest Commercialisation News

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

ClearVue Technologies’ solar façade trial at Hong Kong EMSD headquarters reveals a rapid 2.6-year payback period with government incentives, alongside strong thermal and fire safety performance.

Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.

Hazer Group has successfully raised $10.7 million through a combination of a share placement and a share purchase plan, positioning the company to advance its innovative clean hydrogen and graphite production technology.

Amplitude Energy capped FY25 with record production and revenue, while progressing its East Coast Supply Project and announcing significant board changes.

X2M Connect Limited has launched a $4.9 million capital raising through a Placement and Entitlement Offer to reduce debt and accelerate expansion in IoT, AI, and renewable energy markets.

Redivium Limited has initiated a comprehensive business review and advisor appointment process aimed at exploring restructuring options to enhance long-term shareholder value and governance.

Hazer Group has signed a non-binding MOU with UK’s EnergyPathways to explore a large-scale clean hydrogen facility integrated with the Marram Energy Storage Hub in northwest England.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Bass Oil Limited reported a 4% rise in June oil production alongside advancing plans to acquire the Vanessa gas field, signaling a strategic pivot towards gas sales and resource expansion.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.